Ładuje się......
Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights
A growing number of multi-targeted tyrosine kinase inhibitor (TKI) has undergone testing for hepatocellular carcinoma (HCC). Unfortunately, this enthusiasm has recently been discouraged by a number of negative phase III studies on several anti-angiogenic TKIs in HCC. Several postulations have been m...
Zapisane w:
| Główni autorzy: | , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Baishideng Publishing Group Co., Limited
2014
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3964385/ https://ncbi.nlm.nih.gov/pubmed/24696599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i12.3135 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|